EGFR and non-small cell lung carcinoma: EGFR inhibitors have been approved for the second-line treatment of advanced NSCLC, regardless of EGFR mutational status.[4] However, patients who initially benefit from EGFR-targeted therapy eventually develop resistance and have poor prolongation of survival.